About
Latent Labs builds generative AI foundation models and autonomous agents for protein, antibody, and molecular design. It sells access and collaboration opportunities to biotechnology and pharmaceutical companies, differentiating itself through proprietary models, laboratory validation, and integrated wet-lab capabilities.
Market
Latent Labs competes in generative biology and AI-driven drug discovery, specifically foundation-model software for de novo protein binders, antibodies, and macrocyclic peptides. It positions itself primarily as a model and platform company rather than a conventional biotech building one internal therapeutic pipeline, with browser, API, and partnership-based access. Its differentiation is zero-shot, all-atom, multimodal design combined with laboratory validation, drug-like properties from the first generation, fast no-code workflows, and integration with wet-lab testing.
Primary customers are biotech and pharmaceutical organizations, particularly drug hunters, protein engineers, computational biologists, and antibody/peptide discovery teams seeking to design therapeutic molecules. The platform also serves academic and other research users; the evidence does not specify a particular company-size segment.
At a Glance
Problem
Drug discovery is constrained by the difficulty of designing proteins that bind precisely to challenging biological targets. Conventional discovery often requires large experimental screens, lengthy iteration cycles, and specialized computational expertise; suboptimal starting molecules can create costly downstream failures and extend development timelines. Latent Labs targets this bottleneck by helping drug designers generate high-confidence therapeutic proteins computationally, reducing work that might otherwise require testing millions of candidates to as few as roughly 30 per target.
The central use case is de novo molecular design for previously difficult or untargeted proteins, especially the creation of antibodies, cyclic peptides, nanobodies, and mini-binders for drug discovery. Early research applications include designing ion-channel inhibitors, generating binders for CAR-T-cell therapies, and targeting conserved malaria epitopes at scale. Latent-Y is aimed at making these campaigns accessible to researchers who lack a dedicated computational design team.
Product / Service
Latent Labs provides a web-based, no-code protein-design platform built around generative AI models including Latent-X, Latent-X2, and the autonomous Latent-Y design agent. Users can upload a protein target or describe a therapeutic objective in natural language; the system can reason through target analysis and epitope selection, generate candidate sequences and structures, score and rank them computationally, and produce lab-ready designs for experimental testing. Latent-X generates macrocycles and mini-binders, while Latent-X2 extends the platform to drug-like antibodies and other biologics.
The benefit is faster, more accessible design with fewer wet-lab iterations. Latent-X generates designs in seconds and was validated across seven therapeutic targets, while Latent-Y reports a 67% target-level success rate across nine targets, binding affinities as strong as 5.4 nM, and campaign completion 56 times faster than independent expert estimates. The platform has a free tier for research users, with daily design quotas and additional credits available on demand; commercial partnerships and custom enterprise arrangements are also offered.
Market
Latent Labs competes in generative biology, AI-powered protein engineering, and computational drug discovery. Its competitive set includes Generate:Biomedicines and Isomorphic Labs, which also apply AI to engineer proteins for therapeutic applications, as well as Cradle Bio, a platform-oriented protein-engineering provider. Latent Labs differentiates itself through frontier generative models, direct lab validation, a no-code interface, and a partnership-driven model rather than developing only a small number of proprietary therapeutic candidates.
The company emerged from stealth in February 2025 with $50 million in total funding, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners. By December 2025, Latent Labs said Latent-X1 had been adopted by industry and academic groups worldwide, and its early-access research cohort reported results across cancer immunotherapy, ion-channel biology, and infectious disease. Public materials do not disclose revenue, so the company is best characterized as an early commercial-stage platform with research adoption, paid design-credit access, and selected-partner programs rather than a business with publicly reported revenue.
Founders & Leadership
Funding History
Kindred Capital, Pillar VC
Radical Ventures, Sofinnova Partners
Recent News
SynBioBeta covered Latent Labs' Latent-Y launch, noting a live demonstration and scientific presentation in London held on July 15, 2026.
BI Journal reported that Latent-Y achieved a 67% success rate across nine targets and was launched to accelerate AI-powered drug discovery worldwide.
Latent Labs announced that Latent-Y, described as its first lab-validated drug-design agent, was opened to researchers worldwide through the Latent Labs Platform.
Latent Labs announced the launch of Latent-Y for researchers worldwide, presenting it as a lab-validated drug-design agent available through its platform.
Latent Labs announced an upcoming Research Tier for Latent-Y, scheduled for launch on July 15, 2026, alongside a live event in London.
SynBioBeta profiled Latent Labs' development activity, identifying Latent-Y, launched in March 2026, as a headline product and noting the company's emergence from stealth in February 2025.
Latent Labs launched Latent-Y, an AI agent that autonomously designs antibodies from text prompts and compresses weeks of expert work into hours.
BioPharmaTrend reported that Latent-Y generates antibody candidates directly from written research goals and can move designs from concept to lab-tested molecules.
GenScript announced its wet-lab partnership supporting Latent-X2 innovation. The article describes Latent-X2 as Latent Labs' next-generation model for designing antibodies and peptides with drug-like properties from the first design cycle.
Latent Labs introduced Latent-X2, a frontier AI model for designing high-affinity antibodies with drug-like properties and macrocyclic peptides.
Active Roles
9Business Model
Latent Labs uses a freemium platform model, offering a free tier while permitting commercial use under its beta license. It also pursues paid commercial partnerships and custom collaboration requests beyond the platform’s standard beta capabilities; public evidence does not specify subscription or usage-based pricing.